Cagrilintide: what the research shows
- By Reed Calder
- Last reviewed Nov 3, 2026
- 28 trials, studies and official documents checked
In short
Cagrilintide is a lab-made, long-acting copy of amylin, a hormone the pancreas releases with insulin. It isn’t a GLP-1. It lasts about a week and is injected weekly. On its own, people lost 11.5% of their weight over 68 weeks, against 3.0% on placebo; combined with semaglutide as CagriSema, 20.4%. It isn’t approved anywhere. CagriSema is under FDA review, and the FDA says cagrilintide can’t be used in compounding.
EvidenceCellAnimalHumanLarge randomized trials, all funded by Novo Nordisk
Cagrilintide is also sold online as a “research peptide”, alone or blended with semaglutide or retatrutide. This page covers what the trials found for cagrilintide alone and in CagriSema, how it compares with semaglutide and tirzepatide, the doses the trials used, its side effects, and where it stands legally.
Names and forms you’ll see
| Name | What it is | Approved? |
|---|---|---|
| Cagrilintide | Novo Nordisk’s amylin peptide, studied on its own and with semaglutide | No; in trials |
| AM833, NNC0174-0833 | Development codes used in early studies and trial records | — |
| CagriSema | Cagrilintide and semaglutide, 2.4 mg each, in one weekly pen | No; under FDA review |
| “Cagri”, “CAG” | Labels used on research vials. One listing used “CAG” for a blend of retatrutide and cagrilintide, so the label alone doesn’t tell you what’s inside | No |
| “Cagri-Sema” blend vials | Research vials of cagrilintide mixed with semaglutide. “5 mg” means 5 mg in total on some labels and 5 mg of each on others | No; not CagriSema |
| Pramlintide (Symlin) | An older, short-acting amylin drug, injected before meals with insulin | Yes, for diabetes |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance.
What cagrilintide is
Amylin is a hormone the pancreas releases with insulin after a meal. It slows the stomach, lowers the sugar-raising hormone glucagon and tells the brain you’re full. Natural amylin clumps into fibers and lasts minutes, so the first amylin drug, pramlintide, has to be injected before every meal. Novo Nordisk redesigned the molecule so it doesn’t clump and added a fatty-acid chain so it lasts (Kruse et al., 2021).
Its half-life is 159 to 195 hours, about a week, which is why it’s injected weekly (Enebo et al., 2021). It acts on amylin receptors and on the related calcitonin receptor (Fletcher et al., 2021). That’s a different signal from semaglutide, which acts on GLP-1 receptors, and the reason the two are combined.
What the trials found
Cagrilintide on its own
In a 26-week trial of 706 adults with obesity, weekly doses from 0.3 to 4.5 mg all beat placebo. The 4.5 mg dose cut weight by 10.8%, or 11.5 kg (25.4 lb), against 9.0% on daily liraglutide 3 mg and 3.0% on placebo (Lau et al., 2021).
REDEFINE 1, the large CagriSema trial, also had a group on cagrilintide 2.4 mg alone. Over 68 weeks they lost 11.5% of their weight counting everyone, against 3.0% on placebo, and 31% lost at least 15%. Counting only people who kept taking it, the figure was 11.8%, about 12.5 kg (27.6 lb). Novo Nordisk reported these figures at a 2025 conference; they haven’t been published as a separate paper (Patient Care Online, 2025).
With semaglutide (CagriSema)
In REDEFINE 1, 3,417 adults with obesity or overweight but no diabetes got weekly injections for 68 weeks. Weight fell 20.4% on CagriSema against 3.0% on placebo (Garvey et al., 2025). In 1,206 people with type 2 diabetes, it fell 13.7% against 3.4% (Davies et al., 2025). In a trial in Japan and Taiwan, CagriSema beat semaglutide alone, 18.4% against 11.9% (Yamauchi et al., 2026).
Against tirzepatide
In REDEFINE 4, 809 adults with obesity got CagriSema or tirzepatide 15 mg for 84 weeks. Weight fell 20.2% on CagriSema against 23.6% on tirzepatide, so it missed its goal of showing CagriSema was at least as good. Both sides knew which drug they were taking, and Novo has released the results but not yet published them (Novo Nordisk, Feb 2026).
Blood sugar
In 2,713 people with type 2 diabetes, HbA1c, a three-month average of blood sugar, fell 1.91 points on CagriSema against 1.75 on semaglutide alone over 68 weeks (Buse et al., 2026).
EvidenceCellAnimalHumanRandomized, placebo- or active-controlled
Novo Nordisk paid for every trial in this section, and its employees are co-authors, as the papers disclose. No independent trial exists yet.
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| Cagrilintide alone works as well as semaglutide | Mixed | Studies disagree. In a 32-week trial of 92 people with diabetes, weight fell 8.1% on cagrilintide against 5.1% on semaglutide (Frias et al., 2023), and a 2026 meta-analysis found the two similar (Ahmed et al., 2026). But in REDEFINE 1, 19.1% on semaglutide reached healthy BMI and waist targets against 9.0% on cagrilintide (Busetto et al., 2026) |
| CagriSema beats tirzepatide (Zepbound) | Contradicted | Not in the head-to-head trial: 20.2% against 23.6% (Novo Nordisk, 2026) |
| Stacking it with retatrutide adds weight loss | Untested | Only shown in rats (Petersen et al., 2026). There’s no published study in people |
| It’s gentler on the stomach than a GLP-1 | Untested | Not clearly. Nausea hit 20% to 47% on cagrilintide against 18% on placebo (Lau et al., 2021), and a trial in people who can’t tolerate GLP-1 drugs is still recruiting (ClinicalTrials.gov) |
| It preserves muscle | Untested | No published result. A muscle study is recruiting (ClinicalTrials.gov) |
| You can get it from a compounding pharmacy | Contradicted | The FDA says cagrilintide can’t be used in compounding under federal law (FDA, 2026) |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
Doses the trials used
| Trial | Who | Doses | Length |
|---|---|---|---|
| Lau et al., 2021 | 706 adults with obesity | Cagrilintide 0.3, 0.6, 1.2, 2.4 or 4.5 mg weekly, stepped up over up to 6 weeks | 26 weeks |
| Frias et al., 2023 | 92 adults with type 2 diabetes | Cagrilintide, semaglutide or both, each stepped up to 2.4 mg weekly | 32 weeks |
| REDEFINE 1, 2025 | 3,417 adults with obesity or overweight | Cagrilintide 2.4 mg, semaglutide 2.4 mg or both, weekly, after 16 weeks of step-ups | 68 weeks |
| RENEW 1 | About 300 adults with obesity or overweight | Cagrilintide alone, weekly; results not yet out | 64 weeks |
All doses were injected under the skin once a week, and every trial raised the dose in steps to limit nausea. The most studied dose is 2.4 mg, the amount in CagriSema.
These are the trials’ methods, not a dosing guide. There’s no approved dose, and products sold online aren’t the drug the trials tested; their contents and strength aren’t verified.
Side effects and safety
- Mostly digestive. On cagrilintide alone, 41% to 63% had stomach side effects against 32% on placebo, mostly nausea, constipation and diarrhea, plus injection-site reactions (Lau et al., 2021). In REDEFINE 1, about 1% quit cagrilintide because of nausea (Patient Care Online, 2025).
- CagriSema adds more. Stomach side effects hit 79.6% on CagriSema against 39.9% on placebo, mostly mild to moderate and short-lived (Garvey et al., 2025).
- Serious side effects. A 2026 meta-analysis found more serious side effects on cagrilintide alone than on semaglutide, about 1.8 times as many (Ahmed et al., 2026).
- Heart rhythm. A dedicated study found no meaningful change in the heart’s QT interval up to 4.5 mg (Gabe et al., 2024).
- Kidney and liver. Blood levels were similar in people with poor kidney or liver function after a single dose (Nielsen et al., 2026).
- An open question about blood pressure hormones. Researchers have proposed that amylin drugs may switch on the renin-angiotensin system, even though CagriSema lowered blood pressure in trials. It’s a hypothesis, not a finding (Muskiet et al., 2026).
- Unstudied groups. The trials excluded pregnancy, trials in children are still recruiting, and published results cover at most 84 weeks of use.
Cagrilintide sold online
Because it isn’t approved, any cagrilintide sold today comes from outside the trials, usually as powder in a vial labeled “for research use only”. The FDA says cagrilintide isn’t part of any approved drug and hasn’t been found safe and effective for any condition (FDA, 2026).
- Blends are hard to read. Vials mixing cagrilintide with semaglutide or retatrutide are sold under short labels, and the same “5 mg” can mean the total or each peptide. A dose worked out from the wrong one is off by double.
- No published tests. We found no published study that tested what’s in cagrilintide sold online.
- Sport. Anti-doping researchers have built a test that detects it (Alhalabi et al., 2026).
Our guide to what to look for explains what each test on a lab report proves and how to match it to your batch.
Legal and approval status
- Not FDA-approved, alone or in CagriSema, and not approved anywhere in the world.
- CagriSema is under review. Novo Nordisk applied to the FDA on December 18, 2025, and expects a decision by late 2026 (Novo Nordisk, 2025). We found no decision as of Nov 3, 2026.
- Can’t be compounded. The FDA says cagrilintide and retatrutide cannot be used in compounding under federal law (FDA, 2026).
- Not in the HHS peptide policy. The October 2026 policy covers six other peptides, not cagrilintide (Reuters, 2026).
- Banned in sport. Anti-doping rules ban, at all times, any drug not approved for human use (WADA, 2026).
- The only legal way to take it is in a registered clinical trial, for now.
Trials under way
Twelve trials of cagrilintide or CagriSema, all from Novo Nordisk, are open or about to open: see the list, with sponsor, phase, size and registry links.
Already under way: 7 active, not recruiting and 18 finished with no results posted.
What’s still unknown
- Whether CagriSema lowers heart attacks and strokes. A 7,000-person trial is due to finish in 2027 (REDEFINE 3).
- How well cagrilintide works alone in its own phase 3 trials, which started in late 2025 (RENEW 1).
- How much of the weight lost is muscle.
- What happens over many years of use, and after stopping.
- What’s actually in vials sold online.
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention Cagrilintide. We recheck every month. Last checked Nov 11, 2026.
We found no retracted, withdrawn or flagged studies that mention Cagrilintide.
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Fletcher et al., 2021 | J Pharmacol Exp Ther | No retraction or concern |
| Enebo et al., 2021 | Lancet | No retraction or concern |
| Kruse et al., 2021 | J Med Chem | No retraction or concern |
| Lau et al., 2021 | Lancet | No retraction or concern |
| Frias et al., 2023 | Lancet | No retraction or concern |
| Gabe et al., 2024 | Diabetes Obes Metab | No retraction or concern |
| Davies et al., 2025 | N Engl J Med | No retraction or concern |
| Garvey et al., 2025 | N Engl J Med | No retraction or concern |
| Muskiet et al., 2026 | Lancet | No retraction or concern |
| Alhalabi et al., 2026 | J Pharm Biomed Anal | No retraction or concern |
| Ahmed et al., 2026 | Diabetes Obes Metab | No retraction or concern |
| Yamauchi et al., 2026 | Lancet Diabetes Endocrinol | No retraction or concern |
| Nielsen et al., 2026 | Clin Pharmacokinet | No retraction or concern |
| Buse et al., 2026 | Lancet Diabetes Endocrinol | No retraction or concern |
| Busetto et al., 2026 | Diabetes Obes Metab | No retraction or concern |
| Petersen et al., 2026 | Nat Metab | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is cagrilintide?
A lab-made, long-acting copy of the hormone amylin, made by Novo Nordisk and injected once a week. It’s studied for weight loss and diabetes, on its own and with semaglutide as CagriSema. It isn’t approved.
Is cagrilintide a GLP-1?
No. It acts on amylin and calcitonin receptors, not GLP-1 receptors (Fletcher et al., 2021). That’s why it’s paired with semaglutide, which is a GLP-1.
Is cagrilintide FDA-approved?
No. CagriSema, its combination with semaglutide, has been under FDA review since December 2025 (Novo Nordisk, 2025).
How much weight do people lose on cagrilintide alone?
About 11.5% over 68 weeks on 2.4 mg, against 3.0% on placebo (Patient Care Online, 2025), and 10.8% over 26 weeks on 4.5 mg (Lau et al., 2021).
What is the half-life of cagrilintide?
About a week: 159 to 195 hours (Enebo et al., 2021).
What is the cagrilintide dosage?
There is no approved dose. Trials used 0.3 to 4.5 mg once a week, raised in steps; the most studied is 2.4 mg. That’s how the trials were run, not instructions for anyone.
Is CagriSema better than tirzepatide?
Not in the head-to-head trial: weight fell 20.2% on CagriSema and 23.6% on tirzepatide over 84 weeks (Novo Nordisk, 2026). More on tirzepatide.
Can you take cagrilintide with retatrutide?
The combination has only been studied in rats, where it beat either one alone (Petersen et al., 2026). There’s no published study in people, and neither is approved. More on retatrutide.
What are the side effects of cagrilintide?
Mostly nausea, constipation, diarrhea and injection-site reactions, more often at higher doses (Lau et al., 2021).
Can cagrilintide be compounded?
No. The FDA says it cannot be used in compounding under federal law (FDA, 2026).
Sources
- Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021;64(15):11183-94. PubMed 34288673
- Fletcher MM, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. J Pharmacol Exp Ther. 2021;377(3):417-40. PubMed 33727283
- Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-48. PubMed 33894838
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-72. PubMed 34798060
- Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-30. PubMed 37364590
- Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;393(7):635-47. PubMed 40544433
- Davies MJ, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;393(7):648-59. PubMed 40544432
- Yamauchi T, et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2026;14(6):450-62. PubMed 42009015
- Buse JB, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes Endocrinol. 2026;14(8):662-77. PubMed 42251859
- Busetto L, et al. Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1. Diabetes Obes Metab. 2026;28(10):9317-25. PubMed 42503495
- Ahmed M, et al. Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression. Diabetes Obes Metab. 2026;28(6):4828-36. PubMed 41834765
- Gabe MBN, et al. Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants. Diabetes Obes Metab. 2024;26(12):5805-11. PubMed 39279639
- Nielsen MJF, et al. Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. Clin Pharmacokinet. 2026;65(7):1087-99. PubMed 42228334
- Muskiet MHA, et al. Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy? Lancet. 2026;406(10522):2980-3. PubMed 41207308
- Petersen J, et al. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats. Nat Metab. 2026;8(10):2069-83. PubMed 42744908
- Alhalabi H, et al. In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research. J Pharm Biomed Anal. 2026;273:117418. PubMed 41702251
- Amylin injectable cagrilintide demonstrates weight loss of 11.8% in late-stage trial: Novo Nordisk update. Patient Care Online, September 16, 2025. Article
- Novo Nordisk. CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity. Company release, February 23, 2026. Release
- Novo Nordisk files for FDA approval of CagriSema. Company release, December 18, 2025. Release
- ClinicalTrials.gov. RENEW 1 (NCT07220642), REDEFINE 3 (NCT05669755), NCT07527195 and NCT07607587. RENEW 1, REDEFINE 3, NCT07527195, NCT07607587
- U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. FDA page
- World Anti-Doping Agency. 2026 Prohibited List, section S0. WADA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- U.S. Food and Drug Administration. Global Substance Registration System: Cagrilintide (UNII AO43BIF1U8). GSRS
- U.S. Food and Drug Administration. Global Substance Registration System: Cagrilintide hydrochloride (UNII 3SBY6D7WH7). GSRS
Last reviewed Nov 3, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.